Tatiana M Prowell

Tatiana M Prowell

UNVERIFIED PROFILE

Are you Tatiana M Prowell?   Register this Author

Register author
Tatiana M Prowell

Tatiana M Prowell

Publications by authors named "Tatiana M Prowell"

Are you Tatiana M Prowell?   Register this Author

17Publications

317Reads

10Profile Views

Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.

N Engl J Med 2019 Feb;380(7):612-615

From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research (T.M.P., J.A.B.), and the Oncology Center of Excellence (R.P.), Food and Drug Administration, Silver Spring, and the Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore (T.M.P., J.A.B.) - both in Maryland.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMp1900079
Publisher Site
http://dx.doi.org/10.1056/NEJMp1900079DOI Listing
February 2019

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

J Clin Oncol 2017 Nov 2;35(33):3737-3744. Epub 2017 Oct 2.

Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; Suanna S. Bruinooge, Caroline Schenkel, and Richard L. Schilsky, ASCO, Alexandria, VA; Samantha Roberts, Marina Kozak, Jeff Allen, and Ellen Sigal, Friends of Cancer Research; Samantha Roberts, Genentech, Washington, DC; Gwynn Ison, Julia A. Beaver, Rajeshwari Sridhara, and Tatiana M. Prowell, US Food and Drug Administration, Silver Spring; Thomas S. Uldrick and Andrea M. Denicoff, National Cancer Institute, Bethesda, MD; Nancy U. Lin, Dana-Farber Cancer Institute, Boston; Paul J. Hesketh, Lahey Health Cancer Institute, Burlington, MA; Lia Gore, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO; Stuart M. Lichtman, Memorial Sloan-Kettering Cancer Center, New York, NY; Nancy Roach, Fight Colorectal Cancer, Springfield, MO; Elizabeth Garrett-Mayer, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Eric Rubin, Merck Research Laboratories, Kenilworth, NJ; and Pratik Multani, Ignyta, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.7916DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5692724PMC
November 2017

Seamless Oncology-Drug Development.

N Engl J Med 2016 May 13;374(21):2001-3. Epub 2016 Apr 13.

From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring (T.M.P., M.R.T., R.P.), and the Breast Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (T.M.P.) - both in Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMp1603747DOI Listing
May 2016

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.

Clin Cancer Res 2015 Oct;21(20):4545-51

Office of Hematology and Oncology Products (OHOP), Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3244DOI Listing
October 2015

Pathological complete response and accelerated drug approval in early breast cancer.

N Engl J Med 2012 Jun 30;366(26):2438-41. Epub 2012 May 30.

Office of Hematology Oncology Products, Food and Drug Administration, Silver Spring, MD, USA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/abs/10.1056/NEJMp1205737
Publisher Site
http://dx.doi.org/10.1056/NEJMp1205737DOI Listing
June 2012

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

Oncologist 2010 23;15(4):428-35. Epub 2010 Mar 23.

Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2009-0178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227966PMC
September 2010

Extended adjuvant therapy for breast cancer--how much is enough?

J Natl Cancer Inst 2007 Dec 11;99(24):1825-7. Epub 2007 Dec 11.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djm264DOI Listing
December 2007

Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?

Semin Oncol 2006 Dec;33(6):681-7

Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.08.016DOI Listing
December 2006

Disease-free survival was greater with letrozole than tamoxifen in postmenopausal women with early breast cancer.

ACP J Club 2006 Jul-Aug;145(1):11

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
August 2006

What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?

Oncologist 2004 ;9(5):507-17

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, Maryland 21231-1000, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.9-5-507DOI Listing
January 2005